BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• BioNTech SE (NASDAQ:BNTX) has received a consensus rating of "Moderate Buy" from analysts, with 13 buy ratings and 4 hold ratings out of 17 brokerages covering the company.
• The average 12-month target price from analysts is $135.80, with notable target prices including $155.00 from Truist Financial and $150.00 from Wells Fargo.
• Despite reporting a revenue increase of 102.6% year-over-year, BioNTech's recent quarterly earnings fell short of expectations, posting a loss of ($1.60) per share compared to a consensus estimate of ($1.41).

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seventeen analysts that are covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $135.8022.

BNTX has been the subject of a number of research analyst reports. Truist Financial reiterated a "buy" rating and set a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. The Goldman Sachs Group began coverage on shares of BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target for the company. HC Wainwright decreased their price target on shares of BioNTech from $138.00 to $136.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Finally, Morgan Stanley upped their target price on shares of BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th.

Institutional Investors Weigh In On BioNTech

Large investors have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC purchased a new stake in BioNTech during the first quarter valued at about $288,000. GAMMA Investing LLC raised its position in BioNTech by 5,710.8% during the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock valued at $4,884,000 after purchasing an additional 52,711 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in BioNTech during the fourth quarter valued at about $238,000. Allianz Asset Management GmbH boosted its stake in shares of BioNTech by 44.3% in the 1st quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company's stock valued at $10,989,000 after purchasing an additional 37,075 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of BioNTech in the 1st quarter valued at $357,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Price Performance

BioNTech stock traded down $1.93 during midday trading on Friday, reaching $100.00. 505,409 shares of the stock were exchanged, compared to its average volume of 775,852. The company's fifty day moving average is $109.66 and its 200-day moving average is $105.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The firm has a market cap of $24.04 billion, a PE ratio of -62.50 and a beta of 1.23. BioNTech has a 52 week low of $81.20 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. During the same quarter last year, the business posted ($3.36) EPS. The company's quarterly revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that BioNTech will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.